Albendazole Capsules

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of albendazole capsules in China. Welcome to wholesale bulk high quality albendazole capsules for sale here from our factory. Good service and reasonable price are available.

Albendazole capsules are an oral anthelmintic medication used to treat parasitic worm infections. The active ingredient, albendazole, belongs to the benzimidazole class and works by inhibiting microtubule formation in parasites, leading to their immobilization and death.

Uses:
Albendazole is effective against a variety of helminth infections, including neurocysticercosis (caused by pork tapeworm larvae), hydatid disease (from dog tapeworm larvae), and intestinal parasites like pinworms, roundworms, and hookworms.

Dosage & Administration:
Dosage varies based on infection type and patient weight, typically taken with food to enhance absorption. Treatment may require multiple cycles.

Side Effects:
Common side effects include nausea, abdominal pain, headache, and dizziness. Rare but serious effects include liver enzyme elevation, bone marrow suppression, and allergic reactions.Albendazole is a broad-spectrum antiparasitic, but medical supervision is essential for safe use.

At the same time, our company not only provides pure powders, but also tablets and suspension. If needed, please feel free to contact us at any time.

 

Our Products

Albendazole Powder

Albendazole Tablets

Albendazole Suspension

Albendazole  COA

Albendazole capsules, as a broad-spectrum antiparasitic drug, requires desiccants to maintain its stability during storage and transportation. However, silica-based desiccants (especially silica gel desiccants) may accidentally adsorb the drug components due to their physical adsorption properties, resulting in a decrease in the effective content of the formulation. The following analysis is conducted from three aspects: typical cases, adsorption mechanism, and risk prevention.

Typical Case: Failure of Drug Effect in Sheep Deworming Experiment in South Africa

 

 

In 2013, a research team in South Africa was evaluating the deworming effect of controlled-release albendazole capsules (CRCs) on Trichuris trichiura. They found that the reduction rate of fecal eggs in the experimental group of sheep was not significantly different from that of the control group, and the weight gain of the experimental group was 12% lower than that of the control group. Further investigation revealed that there was an excessive adsorption phenomenon of the silica gel desiccant in this batch of capsules: the residual amount of albendazole detected on the surface of the desiccant was 0.8mg/g, while the drug content in the normal capsule contents was 200mg per pill.

This case reveals two major issues:

The desiccant comes into direct contact with the medicine: The packaging design does not adopt an independent separation structure, resulting in the desiccant and the capsules rubbing against each other during transportation, and the medicine powder adhering to the surface of the desiccant.

Adhesion kinetics imbalance: At 25℃ and a relative humidity of 60%, the adsorption equilibrium time of silica gel desiccant for albendazole is 72 hours, but the actual transportation period is as long as 14 days, far exceeding the adsorption saturation time.

Analysis of the mechanism of drug adsorption by silica gel desiccants

 

 

Surface monolayer adsorption: The silanol groups (-Si-OH) on the silica surface combine with the amino groups (-NH₂) in albendazole molecules through hydrogen bonds, forming the initial adsorption layer. During this stage, the adsorption rate is fast, but the adsorption amount is low (about 0.1mg/g).

Multilayer adsorption: When the surface adsorption sites are saturated, the drug molecules continue to accumulate on the already adsorbed layer through van der Waals forces, forming a multi-layer structure. At this time, the adsorption amount significantly increases, but the adsorption strength decreases.

The adsorption characteristics of albendazole are affected by the following factors:

Molecular polarity: The molecule of albendazole contains sulfur atoms (with an electronegativity of 2.58) and nitrogen atoms (with an electronegativity of 3.04), which are prone to interact with the polar groups on the surface of silica gel.

Crystal structure: The raw material of albendazole is α-type crystal, and its lattice energy (120 kJ/mol) is lower than that of β-type (145 kJ/mol), making it more easily adsorbed.

Environmental humidity: When the relative humidity is greater than 60%, water molecules in the silica gel micropores form liquid bridges, promoting the dissolution and adsorption of drug molecules. Experimental results show that at 80% humidity, the adsorption amount of albendazole is 3.2 times higher than that at 40% humidity.

Risk Control: From packaging design to optimization of testing standards

 

Improvement of testing standards:After being placed at 40℃/75%RH for 6 months, the capsule content and the adsorption amount of the desiccant were regularly tested. The specified adsorption amount was required not to exceed 0.5% of the labeled amount of the capsule; otherwise, it was judged as unqualified.

Packaging structure improvement

 Independent compartment design: Using double-layer aluminum foil packaging, with capsules placed in the inner layer and a desiccant compartment in the outer layer, physical isolation reduces the risk of contact. After this design was applied by a pharmaceutical company, the desiccant adsorption rate decreased from 0.8 mg/g to 0.02 mg/g.

 Application of breathable membrane: Embedding a 0.45 μm pore diameter polytetrafluoroethylene membrane between the desiccant compartment and the capsule compartment allows water molecules to pass through while blocking the drug powder. This technology can reduce the adsorption amount by 95% while maintaining the moisture-proof effect.

Optimization of desiccant selection

Modified silica gel substitution: Using amino-modified silica gel (such as NH₂-SiO₂), the surface amino groups of the modified silica gel compete for adsorption with the albendazole molecules, reducing the adsorption amount. Experimental results show that the adsorption amount of modified silica gel for albendazole is 78% lower than that of ordinary silica gel.

Application of composite desiccant: Using a silica gel-chloride calcium composite desiccant, the chemical hygroscopicity of calcium chloride (with a hygroscopic capacity of up to 300% of its own weight) reduces the amount of silica gel used, thereby reducing the adsorption risk. 

Industry Insights and Future Directions

 

The problem of drug adsorption by silica gel is not an isolated case; its essence is the contradiction between drug stability and the compatibility of packaging materials. Future research can focus on the following directions：

Development of intelligent desiccants

Develop temperature and humidity-responsive desiccants that maintain their hygroscopic activity during storage and automatically seal the pore structure during transportation.

Computational simulation-assisted design

Use molecular dynamics simulation to predict the interaction between drugs and desiccants, and optimize packaging materials and process parameters.

Blockchain traceability system

Establish a full-chain database for desiccant production and use, enabling real-time monitoring and early warning of adsorption risks.

Through collaborative innovation in materials science, packaging engineering, and pharmaceutical technology, the problem of drug adsorption by desiccants can be systematically solved, providing quality assurance for the global supply of anti-parasitic drugs such as albendazole. 

Albendazole capsules, as a broad-spectrum deworming drug, the bioavailability of its capsule formulation is significantly influenced by the capsule shell material. Gelatin capsules and vegetarian capsules (such as hydroxypropyl methylcellulose capsules, starch capsules, etc.) exhibit different characteristics in terms of drug release, stability and absorption efficiency due to differences in material properties, thereby affecting the bioavailability.

The bioavailability characteristics of gelatin capsules

Gelatin capsules are made by hydrolyzing animal collagen. The amino and carboxyl groups in the molecular chains of the capsules give them good flexibility and sealing properties, but there is also a risk of cross-linking reaction. The lysine and arginine residues in gelatin are prone to oxidation under high temperature and high humidity conditions to form aldehyde groups, which further combine with adjacent amino groups to form amine acetal structures, causing the capsules to harden. This cross-linking reaction significantly reduces the swelling and solubility of the capsules, thereby delaying the drug release. For example, after an accelerated test at 40°C/75%RH for 8 days, the dissolution rate of cross-linked gelatin capsules decreased by 40% compared to the non-cross-linked samples, which may lead to a delay in drug absorption in the gastrointestinal tract.

Furthermore, the bioavailability of gelatin capsules is also influenced by the composition of the contents. If the raw materials or excipients of albendazole contain aldehyde compounds (such as certain stabilizers), they will directly react with the amino groups of gelatin, accelerating the cross-linking process. This interaction may alter the drug release curve, reducing the peak blood drug concentration (Cmax) or delaying the time to reach the peak concentration (Tmax), especially for drugs with a narrow absorption window (such as the metabolite of albendazole that needs to be absorbed in a specific part of the small intestine), the effect is more significant.

Vegetarian capsules are manufactured using plant-based materials such as hydroxypropyl methylcellulose (HPMC), starch, and pullulan polysaccharide. Unlike gelatin, their molecular structure lacks amino groups, which fundamentally eliminates the risk of cross-linking reactions that can compromise drug stability and dissolution performance. Taking HPMC capsules as a representative example, their unique mechanism of shell swelling and drug release relies on the formation of hydrogen bond networks upon contact with gastrointestinal fluids, ensuring a controlled and predictable release profile. 

Vegetarian capsules are made of plant-based materials (such as hydroxypropyl methylcellulose, starch, pullulan polysaccharide, etc.), and their molecular structure does not contain amino groups, fundamentally avoiding the occurrence of cross-linking reactions. For example, HPMC capsules promote the swelling and drug release of the capsule shell through hydrogen bond networks, and have low hygroscopicity. They are less likely to crack in low humidity environments and less likely to stick together in high humidity environments, ensuring the consistency of drug release. 

Starch capsules (such as cassava starch-based capsules) provide stable protection for powder or liquid contents due to their branched starch structure and excellent water resistance. They have a low moisture content (4%-6%) and strong chemical stability, ensuring that albendazole's active ingredients do not decrease during storage. Moreover, the manufacturing process of plant capsules does not require the addition of preservatives or the use of ethylene oxide sterilization, avoiding potential chemical residues that could affect the stability of the drug, and further ensuring bioavailability.

Process Optimization and Future Trends

 

To address the cross-linking defects of gelatin capsules, manufacturers have improved bioavailability by adding antioxidants (such as glycine, sodium metabisulfite) or adopting enteric coating technology. However, these methods may increase process complexity and costs. On the other hand, vegetarian capsules, due to their chemical inertness, environmental adaptability, and process controllability, are gradually becoming the preferred choice for high-end preparations.

The global market for plant-based capsules is growing at an annual rate of 25%, and is expected to exceed $5 billion in size by 2030. They particularly have significant advantages in traditional Chinese medicine preparations and biopharmaceuticals. In the future, with the application of innovative materials such as modified starch and nanotechnology, the dissolution performance and cost competitiveness of vegetarian capsules will further improve, providing a more reliable delivery solution for anti-parasitic drugs like albendazole and others.

• What is albendazole used for?

Albendazole is an FDA-approved medication for treating a variety of parasitic worm infections. Albendazole is an antihelminthic medication with numerous indications such as cystic hydatid disease of the liver, lung, and peritoneum resulting from the larval form of the dog tapeworm, Echinococcus granulosus.

• When should albendazole be taken?

It is usually taken with food twice a day. When albendazole is used to treat neurocysticercosis, it is usually taken for 8 to 30 days. When albendazole is used to treat cystic hydatid disease, it is usually taken for 28 days, followed by a 14-day break, and repeated for a total of three cycles.

Hot Tags: albendazole capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale